Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes

Cancers(2022)10.3390/cancers14133257Source: DataRank Database

A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0.483. It has been cited 24 times.

N/A

0.483DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.75)OA: goldTopics (26)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.483

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (8)

Jung Kim ORCID,Jeremy S. Haley ORCID,Sun Young Kim ORCID,H. Shanker Rao ORCID,David J. Carey ORCID

Live enrichment

PubMed:35805029 PMC:PMC9265005 OpenAlex:https://openalex.org/W4283782560

the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, NIH, Bethesda, MD

Grant: T32GM007471

Medical Research Council

Grant: MC_PC_17228

Medical Research Council

Grant: MC_QA137853

National Institutes of Health

Grant: 5T32GM007471-13

MEDICAL GENETICS

FWCI

4.75

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/14/13/3257/pdf?version=1656997736

publisherhttps://www.mdpi.com/2072-6694/14/13/3257/pdf?version=1656997736

publisherhttps://www.mdpi.com/2072-6694/14/13/3257/pdf

journalhttps://doi.org/10.3390/cancers14133257

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35805029

Fields of Study

Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsBRCA gene mutations in cancer0301 basic medicine03 medical and health sciences

Keywords

CHEK2PALB2CDKN2AGermlineCancerPancreatic cancerPopulationGeneticsGeneBiologyCancer researchMedicineOncologyGermline mutationMutationEnvironmental healthPancreatic Ductal AdenocarcinomaCancer RiskInherited CancerCancer GeneticsArticle

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Prevalence of BRCA1 and BRCA2 germline variants in an unselected pancreatic cancer patient cohort in Pakistan

10.6084/m9.figshare.26638803.v1figshare

Additional file 1 of Prevalence of BRCA1 and BRCA2 germline variants in an unselected pancreatic cancer patient cohort in Pakistan

10.6084/m9.figshare.26638803figshare

Additional file 2 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721087.v1figshare

Additional file 2 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721087figshare

Additional file 8 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721105.v1figshare

Additional file 8 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721105figshare

Additional file 12 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721117.v1figshare

Additional file 12 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721117figshare

Additional file 10 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721111.v1figshare

Additional file 16 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721129.v1figshare

Additional file 13 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721120.v1figshare

Additional file 15 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721126figshare

Additional file 13 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721120figshare

Additional file 4 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721093.v1figshare

Additional file 4 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721093figshare

Additional file 17 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721132.v1figshare

Additional file 6 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721099.v1figshare

Additional file 17 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721132figshare

Additional file 5 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721096.v1figshare

Additional file 16 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

10.6084/m9.figshare.26721129figshare